ADAM17 Antibody (YA4137)

ADAM17 (A Disintegrin and Metalloprotease 17), also known as TNF-α-converting enzyme (TACE), is a membrane-associated metalloprotease that regulates cell-cell communication through ectodomain shedding of cytokines, receptors, adhesion molecules, and growth factor ligands^[1][2]. Mechanistically, ADAM17 is a major sheddase for tumor necrosis factor-α (TNF-α), interleukin-6 receptor (IL-6R), and multiple epidermal growth factor receptor (EGFR) ligands, thereby coordinating inflammatory, regenerative, and proliferative signaling pathways^[2][3][4]. Through the generation of soluble TNF-α and soluble IL-6R, ADAM17 functions as a central signaling hub linking immune activation with systemic inflammatory responses^[2][4]. In addition, ADAM17-dependent shedding of EGFR ligands regulates EGFR signaling in epithelial tissues and contributes to processes associated with tissue homeostasis, development, and tumor progression^[3][5][6]. Disease studies further demonstrate that ADAM17 participates in inflammation, cancer, and other pathological conditions through its broad substrate repertoire and downstream signaling effects^[1][2][6]. Compared with the closely related metalloprotease ADAM10, ADAM17 displays distinct substrate specificity and serves as the predominant sheddase for amphiregulin, transforming growth factor-α (TGF-α), epiregulin, and heparin-binding EGF-like growth factor (HB-EGF), whereas ADAM10 preferentially processes other EGFR ligands^[7][8]. This functional distinction is important for experimental design because selective modulation of ADAM17 can differentially affect TNF-α, IL-6, and EGFR signaling networks^[2][7]. For research applications, ADAM17 inhibitors and blocking antibodies are widely used to investigate cytokine release, inflammatory signaling, EGFR activation, and tumor-associated microenvironmental interactions in cellular and animal models^[2][9].